Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP-B31. - Tan-Chiu,E.; Yothers,G.; Romond,E. (J Clin Oncol, 2005)